Pricing Log in Create free account

Myriad Genetics, Inc. (MYGN) vs Exagen Inc. (XGN)

Myriad Genetics, Inc. and Exagen Inc. are both Diagnostics & Research companies. Myriad Genetics, Inc. is the larger, with a market value of $416.1M against $207.4M — 2.0× the size. Exagen Inc. grew revenue faster over the last twelve months: 20.8% against −3.16%. Myriad Genetics, Inc. has the higher net margin (−14.0% vs −26.6%) and the higher return on invested capital (−19.9% vs −68.3%). Across the 18 metrics below, Myriad Genetics, Inc. leads on 12 and Exagen Inc. on 6.

Valuation

Metric MYGN XGN Diagnostics & Research median
P/E n/m n/m 35.56
P/S 0.47 2.60 4.37
P/B 1.24 15.13 3.06
Price to free cash flow n/m n/m 35.76
EV/EBITDA n/m n/m 24.35
EV/Sales 0.55 2.60 5.51
Earnings yield (29.90%) (10.59%) (1.89%)
Free cash flow yield (3.76%) (4.10%) (0.15%)

Profitability

Metric MYGN XGN Diagnostics & Research median
Gross margin 68.83% 58.64% 50.89%
Operating margin (12.22%) (18.58%) (8.57%)
Net margin (13.96%) (26.61%) (6.37%)
Free cash flow margin (1.76%) (10.66%) 0.00%
Return on equity (32.54%) (113.82%) (2.92%)
Return on assets (17.11%) (34.19%) (6.71%)
Return on invested capital (19.92%) (68.33%) 0.00%

Growth

Metric MYGN XGN Diagnostics & Research median
Revenue growth (TTM) (3.16%) 20.83% 7.69%
EPS growth (last fiscal year) (180.14%) (12.05%) 25.92%
Revenue growth, 5-year CAGR 3.61% 9.66% 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MYGN XGN Diagnostics & Research median
Debt to equity 0.40 2.00 0.11
Current ratio 2.21 3.18 2.02
Net debt to EBITDA 2.11 0.68 0.70

Dividend

Metric MYGN XGN Diagnostics & Research median
Dividend yield — — 0.66%
Payout ratio — — 0.20

Size

Metric MYGN XGN Diagnostics & Research median
Market cap 416.08m 207.37m 2.16b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack